Perhaps more so than any other tissue, bone has pivotal mechanical and biological functions. Underlying the ability of bone to execute these functions, whether providing structural support or preserving mineral homeostasis, is the dynamic remodeling of bone matrix. Cells within bone integrate multiple stimuli to balance the deposition and resorption of bone matrix. Transforming growth factor-b (TGFb ) uniquely coordinates bone cell activity to maintain bone homeostasis. TGFb regulates the differentiation and function of both osteoblasts and osteoclasts, from lineage recruitment to terminal differentiation, to balance bone formation and resorption. TGFb calibrates the synthesis and material quality of bone matrix and bone's responsiveness to applied mechanical loads. Therefore, by coupling the activity of bone forming and resorbing cells, and by sensing, responding to and defining physical cues, TGFb integrates physical and biochemical stimuli to maintain bone homeostasis. Disruption of TGFb signaling has significant consequences on bone mass and quality. Alternatively, TGFb is a powerful lever that has the potential to yield therapeutic benefit in cases where bone homeostasis needs to be recalibrated.
remodeling. Briefly, bone remodeling involves the sequence of osteoclast recruitment and differentiation, bone matrix resorption and a reversal phase in which osteoblasts are recruited to the resorption site where they deposit new bone matrix. Osteoblasts ultimately become embedded in the bone matrix as mature osteocytes. TGFb is intimately involved in each stage of this process. TGFb regulates the recruitment, differentiation and function of both osteoblasts ( Figure 1 ) and osteoclasts ( Figure 2) , as well as the crosstalk mediating bone remodeling and the quality of bone matrix.
Regulation of Osteoblasts by TGFb
At the cellular level, TGFb acts on the osteoblast lineage to expand the pool of bone matrix-secreting cells. TGFb has long been known to act as a chemoattractant for osteoprogenitor cells. 4 TGFb recruits osteoprogenitors to the site of new bone formation or remodeling. 5 In bone fractures, osteoprogenitors migrate toward the site of fracture repair, following a gradient of TGFb released from platelets and injured bone. [6] [7] [8] TGFb also increases the number of osteogenic cells by stimulating osteoprogenitor proliferation, in part by promoting the degradation of the cell cycle inhibitor p57 Kip2 . 9 As it does throughout the body, TGFb regulates the synthesis of extracellular matrix proteins and proteases in bone, including alkaline phosphatase, collagen I, osteocalcin, osteopontin, and matrix metalloproteinase-13 (MMP-13). 10 Initially, TGFb stimulates bone matrix synthesis, perhaps as a function of its expansion of the osteoprogenitor population. However, TGFb later inhibits terminal osteoblast differentiation and bone matrix synthesis by Smad3-dependent repression of Runx2 expression and function ( Figure 1 ). 11 TGFb also acts on terminally differentiated osteocytes by inhibiting osteocyte apoptosis, in part through a Smad3 and vitamin D receptor-dependent mechanism. 12 Therefore, TGFb plays a distinct role at each stage of the osteoblast life cycle. Figure 1 Transforming growth factor-b (TGFb ) regulates the recruitment, differentiation, and function of osteoblasts. The TGFb -activated Smad3 represses Runx2 function to inhibit osteoblast differentiation. This osteoblast-dependent pathway is also responsible for the ability of TGFb to regulate bone matrix elastic modulus, or stiffness, and it relies upon the action of Runx2.
Figure 2
Transforming growth factor-b (TGFb ) couples bone formation with resorption through the regulation of osteoblast-derived osteoclast regulatory factors. Osteoclasts also release and activate TGFb stored in latent form in the bone matrix during resorption through creating an acidic microenvironment as well as through the secretion of matrix metalloproteinases MMP-2 and MMP-9, which proteolytically activate TGFb . The active TGFb released during osteoclast-mediated bone resorption feeds back on osteoblasts. TGFb 1-directed migration of bone-derived mesenchymal progenitors to resorptive sites is an essential step in the coupling process. By inducing osteoprogenitor recruitment and proliferation, TGFb balances matrix resorption with new bone deposition.
Regulating postnatal bone homeostasis by TGFb SY Tang and T Alliston

Regulation of Osteoclasts by TGFb
The effect of TGFb on osteoclasts also depends upon the stage of osteoclast differentiation. 13 TGFb promotes the chemotaxis of isolated osteoclast precursors into bone, 14 and it later stimulates osteoclast precursor proliferation and differentiation. [15] [16] [17] [18] TGFb can act directly on osteoclasts and their precursors through its type I and type II TGFb receptors. However, many of the effects of TGFb on osteoclasts are indirect. For example, TGFb acts on osteoblasts to regulate the expression of osteoclast regulatory proteins including M-CSF, RANKL, OPG, ephrin B2 and EphB4 ( Figure 2 ). 19, 20 At low doses, TGFb treatment enhances osteoclastogenesis by increasing M-CSF expression and prostaglandin production, as well as the RANKL to OPG ratio. 21 In contrast, high TGFb levels repress M-CSF and RANKL expression while increasing OPG expression. [22] [23] [24] Because high levels of TGFb do not inhibit osteoclastogenesis in pure osteoclast cultures, the inhibitory effects of TGFb at high doses are mediated by osteoblasts and thus may serve as a negative feedback loop to limit bone resorption. 13 
Coupling of Bone Resorption and Bone Formation by TGFb
The ability of TGFb to regulate osteoblast-derived osteoclast regulatory factors is one of the mechanisms by which TGFb couples bone formation with resorption. 2, 13 Moreover, during bone resorption, osteoclasts release and activate TGFb stored in latent form in the bone matrix. The acidic microenvironment created by osteoclasts directly activates the TGFb ligand from the latent complex. In addition to secreting TGFb, osteoclasts also secrete matrix metalloproteinases MMP-2 and MMP-9 that, along with cathepsin K, can proteolytically activate TGFb. [25] [26] [27] The active TGFb released during osteoclastmediated bone resorption feeds back on osteoblasts. The TGFb 1-directed migration of bone-derived mesenchymal progenitors to resorptive sites is an essential step in the coupling process. 5 By inducing osteoprogenitor recruitment and proliferation, TGFb balances matrix resorption with new bone deposition. Although many questions remain about the bone remodeling compartment canopy, 28,29 such a structure may create a microenvironment that limits the diffusion of TGFb and other growth factors released from the bone matrix by osteoclasts while facilitating the local recruitment of progenitors.
Osteocyte-Mediated Perilacunar Remodeling and TGFb
Osteocytes, the most abundant bone cells embedded in lacunae throughout the bone matrix, have recently been shown to modify their perilacunar matrix. Under physiological stress of lactation, cortical bone osteocytes express several proteins, including proteases, that allow these cells to resorb their local bone matrix to release mineral into the circulation for milk production. The lacunae around these TRAP-positive osteocytes enlarge with lactation and return to normal following weaning as the local bone matrix is replaced. 30 This lactationmediated perilacunar remodeling requires MMP-13. 30, 31 Even in normal conditions, perilacunar remodeling is required to maintain the collagen and mineral organization of cortical bone matrix and the ability of bone to resist fracture. The expression of MMP-13 is tightly regulated by TGFb, parathyroid hormone, glucocorticoids and other factors. [32] [33] [34] [35] TGFb has also been shown to be important for the stability of osteocytes, 36 and it may be possible that osteocytes may exert their actions on the matrix through the TGFb -mediated regulation of proteases such as MMP-13. 33, 34 Taken together, maintaining the stability of osteocytes and the osteocytic-mediated dynamic remodeling of perilacunar bone matrix may be yet another way in which TGFb regulates bone homeostasis.
Regulation of Bone Mass and Bone Quality by TGFb
Several mouse models demonstrate the consequences of altering TGFb signaling on bone mass. Given the multiplicity of TGFb activities on osteoblasts, osteoclasts and osteocytes, it should not be surprising that these phenotypes fail to reveal a simple anabolic or catabolic role for TGFb in bone. For example, a low bone mass phenotype results from mutations that increase TGFb signaling (by overexpression of the activated ligand 37 ), as well as from those that reduce it (by ablation of the key TGFb effector Smad3). 12 Rather, these mouse models clearly illustrate the key role of TGFb in the intricate coupling of osteoblast and osteoclast activity during bone remodeling, and the subsequent effects on bone quality and fracture resistance. 38 Many of the bone phenotypes become more severe with age, consistent with the importance of TGFb in maintaining postnatal bone mass. 12, 37, 39 In addition to bone mass, the fracture resistance of bone is determined by several other factors including the bone microarchitecture, geometry and extracellular matrix material properties. 40, 41 Each of these factors is biologically defined by a number of key signaling molecules. Consequently, mice with mutations in the TGFb pathway exhibit alterations in other aspects of bone quality as well. In particular, TGFb regulates bone matrix material properties. 38 Unlike bone mass, this effect is dose dependent, such that the elastic modulus of bone matrix is reduced in genetically modified mice with elevated TGFbsignaling; but increased in those that have lower TGFb signaling activity. 38 Similarly, postnatal pharmacologic inhibition of TGFb type I receptor function is sufficient to increase the elastic modulus of bone matrix, demonstrating that these properties are regulated postnatally and must be maintained. 20, 38 TGFb regulates bone matrix elastic modulus, or stiffness, through an osteoblast-dependent mechanism that relies upon the action of Runx2. 42 Just as TGFb -activated Smad3 represses Runx2 function to inhibit osteoblast differentiation, 11, 42 this pathway is also employed to control bone matrix stiffness (Figure 1) . Although TGFb also regulates the material quality of skin, tendon and dentin matrix, [43] [44] [45] the extent to which it also targets master transcriptional regulators to do so remains unclear.
TGFb as an Integrator of Physical and Biochemical Stimuli in Bone
The ability of TGFb to regulate bone matrix material properties may be important for the mechanical and biological function of bone. Bone matrix material properties are biologically regulated and anatomically distinct, suggesting that this regulation offers a selective advantage to the organism. The functional significance of this regulation for long bone fracture resistance has so far proven difficult to distinguish from the many other factors that affect bone quality. Nonetheless, analyses of a unique bone, the cochlea, revealed that each GPa decrement in Regulating postnatal bone homeostasis by TGFb SY Tang and T Alliston elastic modulus was responsible for nearly 2 dB of hearing loss, which may contribute to the hearing loss in patients with cleidocranial dysplasia. 42, 46, 47 Although the ability of osteocytes to regulate bone matrix stiffness in response to TGFb is yet unknown, in light of recent studies, it is intriguing to consider the possibility that osteocytes have the capacity to quickly change the material quality of the perilacunar bone matrix. This could be particularly important as extracellular matrix stiffness itself is a potent regulator of osteoblast gene expression and cellular apoptosis. 12, 48, 49 Factors that change extracellular matrix stiffness may in turn alter the physical cues in the cellular microenvironment to direct bone cell behavior.
Just as TGFb maintains bone mass and quality in response to changing biological conditions, it also participates in the anabolic response of bone to mechanical load. In bone and many other tissues, the expression of TGFb ligands responds to physical stimuli including fluid flow and compressive loads. 50 Using an in vivo hind-limb loading model, we recently found that mechanical loading of bone represses TGFb signaling through Smad2/3. 51 This mechanosensitive regulation of TGFb is essential for the anabolic response of bone to mechanical loads. In this way, TGFb is critical for the ability of bone to continuously adapt to changing stimuli-both biological and physical.
Human Pathologies
Given its critical roles in directing bone cell fate and the coupling of osteoblast/osteoclast interactions, it is perhaps not surprising that disruptions in TGFb signaling have been implicated in deregulation of bone mass and quality in several human pathologies as it does in several mouse models. 12, 20, [37] [38] [39] 52 These studies have shown that increased TGFb signaling reduces bone mass and bone quality, producing a bone phenotype that is similar to osteoporosis. Other skeletal pathologies due to deregulation of TGFb signaling include Camurati-Engelmann disease and osteopoikilosis. Camurati-Engelmann disease, also known as progressive diaphyseal dysplasia, is characterized by hyperostosis and sclerosis of the base of the skull and the long-bone diaphyses. Camurati-Engelmann disease is the result of TGFB1 mutations in either a signal peptide or the latency-associated propeptide, 53-55 and these mutations result in increased levels of bioactive TGFb 1 and subsequently increased TGFb signaling. 56 In this case, the deregulated activation of TGFb 1 results in hyperactive formation of fragile bone. 5, 55, 56 Osteopoikilosis is a skeletal dysplasia characterized by symmetric but unequal distribution of hyperostotic regions across the skeleton, with variants that also include sclerosis of the skin. Osteopoikilosis can be attributed to the loss of LEMD3 (LEM domain-containing 3), which confers increased bone morphogenetic protein and/or TGFb signaling. [57] [58] [59] These diseases illustrate the essential role of TGFb in bone homeostasis, and the dramatic effects that result from the deregulation of TGFb.
Therapeutic Potential
Many studies have investigated the therapeutic utility of manipulating the TGFb pathway in the skeleton, through the direct administration of TGFb or the regulation of TGFb effectors. For example, the inhibition of TGFb signaling, either by the pharmacologic inhibition of the TGFb type I receptor 5, 20 or by TGFb blockade using antibodies, 28, 29, 60 exerts positive effects on both bone mass and bone matrix quality that culminate in improved fracture resistance. Antagonizing TGFb also protects bone from breast cancer metastasis. 61 Importantly, the effect of TGFb critically depends on the cell and tissue context. 3 In particular, TGFb signaling has distinct effects during different stages of the bone regenerative response and has critical roles in the intramembranous ossification process during fracture healing. The exogenous delivery of TGFb enhances bone regeneration around bone implants over a 4week period with increased regenerated bone volume fraction, bone contact area and reduced implant-tissue gap, 62 likely because of the ability of TGFb to recruit osteoprogenitors to the implant site. Numerous studies have explored mechanisms by which TGFb enhances the bone regenerative response and bone union during fracture healing. These result in part from the ability of TGFb to promote chondrogenesis. This complements the ability of TGFb released from bone and platelets following trauma to mobilize mesenchymal stem cells and osteoprogenitors to the injury site. 63 In addition, TGFb calibrates the timing of chondrocyte and osteoblast differentiation in order to ensure an adequate cell population for repair before ossification of the fracture site. 64 
Conclusion
As bone remodeling is critical for the metabolic and mechanical roles of the bone, TGFb maintains bone homeostasis by coupling the osteoblast and osteoclast activity, mediating the biological responsiveness towards mechanical stimuli, mobilizing stem cells, and calibrating the differentiation of bone forming and resorbing cells. Disruption of TGFb signaling has adverse consequences in bone mass, quality, and regeneration. Because of the potent effects of TGFb, leveraging TGFb signaling for the directed homeostatic and regenerative response of bone may provide valuable therapeutic benefits.
